ASO/siRNA Screening and Validation

ASO/siRNA Screening and Validation

1. Background

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) represent a new generation of precision nucleic acid therapeutics. By sequence-specifically recognizing and engaging target RNAs, they enable precise modulation of gene expression at the RNA level. These modalities have emerged as pivotal tools for the treatment of rare diseases, inherited disorders, neurodegenerative conditions, and metabolic diseases. ASOs primarily act through RNase H-mediated mRNA degradation or steric blocking of RNA function, while siRNAs rely on the RNA-induced silencing complex (RISC) to cleave target mRNAs, offering superior target specificity. Compared with conventional small-molecule drugs and antibody-based therapeutics, nucleic acid medicines offer distinct advantages: broad target space, shortened design cycles, and sequence-customizable structures—enabling therapeutic intervention against targets previously considered undruggable. As a result, nucleic acid drugs have secured a strategically critical position in global biopharmaceutical R&D pipelines.

The clinical and commercial viability of ASO and siRNA drugs has been well validated, with multiple approved products addressing conditions including spinal muscular atrophy (SMA), hereditary transthyretin-mediated amyloidosis (hATTR), acute hepatic porphyria (AHP), and hypercholesterolemia. The global nucleic acid drug pipeline continues to expand, with a growing number of candidates entering preclinical and clinical development, representing one of the most high-growth segments in contemporary biopharmaceutics.

Nevertheless, the success rate of nucleic acid drug development is critically dependent on precise sequence design and comprehensive safety profiling. From candidate sequence design to Lead ASO/siRNA confirmation, the process encompasses multiple complex steps: sequence optimization, off-target risk assessment, delivery strategy selection, and in vitro validation. Safety risks associated with ASOs and siRNAs arise from two principal dimensions: (1) sequence-dependent (hybridization-dependent) off-target effects—due to high sequence similarity, a drug may engage non-target genes through unintended hybridization, leading to aberrant expression of non-target genes, a major source of preclinical toxicity signals; and (2) sequence-independent effects—such as class effects of ASOs (e.g., complement activation, coagulation interference) and siRNA-mediated innate immune stimulation via TLR7/TLR8 activation. In recent years, ICH, major global regulatory agencies (FDA, EMA, PMDA, CDE), and the Oligonucleotide Safety Working Group (OSWG) have published dedicated technical guidance documents establishing clear and systematic requirements for ASO/siRNA safety assessment.

Figure 1. Overview of key guidance documents from ICH/FDA/EMA/PMDA/CDE

ZhuHai GeneRulor has developed a deep understanding of regulatory guidance and industry consensus. Drawing on years of safety evaluation service experience, and integrating state-of-the-art bioinformatics algorithms with an expert experimental validation platform, we have established a fully integrated, one-stop screening and validation system—spanning from target design to Lead ASO/siRNA confirmation—enabling our clients to rapidly, cost-effectively, and efficiently identify ASO/siRNA candidates with strong clinical translational potential.

2. Service Positioning and Technical Workflow

We employ a phased funnel strategy of "Design → Synthesis → Screening → Optimization → Confirmation" to systematically identify optimal molecules from large candidate pools. Differentiated screening and validation strategies are provided based on the distinct mechanisms of action and technical characteristics of ASOs and siRNAs.

ASO Screening Workflow: Utilizing 2'-MOE gapmer and other chemical modification strategies, with a focus on evaluating RNase H activity, target accessibility, RNA secondary structure impact, and gymnotic uptake capacity (intracellular delivery efficiency in the absence of transfection reagents), providing critical data to support in vivo applications.

siRNA Screening Workflow: Comprehensive evaluation of guide strand and passenger strand off-target risks; optimization of chemical modification sites (2'-OMe, 2'-F, etc.); validation of RISC loading efficiency; assessment of seed region off-target potential; and potency verification tailored to the selected delivery modality (lipid nanoparticle/LNP, GalNAc conjugation, etc.).

Phased Funnel Screening Process: Through four progressive stages, high-efficiency screening is achieved from a large candidate pool down to Lead molecules:

① Intelligent Design—Multi-algorithm integration and transcriptome-wide off-target analysis rapidly generate a high-quality candidate pool (50+ ASOs; 30–50 siRNAs per target gene). In silico pre-screening identifies Top candidates for experimental validation.

② High-Throughput Primary Screening—Three-concentration gradient assay enables rapid potency assessment, combined with preliminary off-target risk evaluation, to select the Top 5 candidates with the best overall performance.

③ Lead Optimization—Full dose-response relationship validation; dual confirmation at mRNA and protein levels; precise determination of therapeutic window. For siRNA candidates, additional evaluation of immunogenicity and durability is performed, yielding Top 2–3 Lead candidates.

④ Lead Confirmation—Simulation of in vivo delivery environments (gymnotic uptake for ASOs; LNP/GalNAc delivery for siRNAs) to predict in vivo efficacy; final confirmation of 1–2 Lead molecules ready to enter preclinical studies.

Our services are designed to provide biopharmaceutical companies, academic research institutions, and clinical investigators with a systematic screening and validation service from computer-aided design through Lead ASO confirmation—significantly compressing development timelines and reducing early-stage development risks.

Figure 2. Phased screening strategy workflow

3. Technical Advantages

（1）Regulatory-Aligned Data Ready for IND Submission

All work strictly adheres to international standards including the FDA 2024 Guidance on Nonclinical Safety Assessment for Oligonucleotide-Based Therapeutics, the OSWG 2024 Off-Target Assessment Guidelines, and the N-of-1 Collaborative 2023 Consensus. All experimental parameters, control group designs, and data analysis methodologies are fully traceable to FDA guidance and published literature, meeting regulatory expectations and preventing IND submission delays due to data quality concerns.

（2）Cost-Optimized Strategy Delivering 30–50% Cost Savings vs. Conventional Approaches

Through phased screening with clearly defined elimination criteria at each decision node, unnecessary comprehensive validation of low-quality candidates is avoided. For example, the primary screening stage requires only three concentration points to eliminate 50% of candidates, significantly reducing downstream validation costs. Overall, costs are reduced by 30–50% compared to one-time comprehensive validation of all candidates, with timelines shortened by more than 25%.

（3）Multi-Dimensional Validation System Ensuring Lead Quality

Validation extends beyond mRNA quantification to encompass protein confirmation (Western Blot), gymnotic uptake assessment, cytotoxicity profiling, and therapeutic window analysis. IC50/EC50 values are precisely calculated using a four-parameter logistic (4PL) model. This comprehensive evaluation ensures that selected Lead molecules demonstrate high translational success rates, guarding against scenarios where candidates excel by a single metric but fail in overall development.

（4）Deep Expertise Benchmarked Against FDA-Approved Drugs

Our screening and validation system is built upon the development pathways of commercially approved ASO/siRNA drugs and guidance documents issued by major global regulatory agencies. Our screening strategies, quality control standards, and data analysis methodologies have been validated across numerous projects, achieving a success rate exceeding 85%.

4. Applications

(1) Early-stage drug discovery: Rapid evaluation of the efficacy and safety profiles of multiple ASO/siRNA candidate sequences to support target validation and lead compound identification.

(2) IND-enabling studies: Provision of systematic screening and validation datasets meeting FDA/EMA regulatory requirements, supporting CMC (Chemistry, Manufacturing, and Controls) development and nonclinical safety assessment.

(3) Lead optimization decisions: In-depth validation of candidate molecules to provide a robust evidence base for progression into in vivo studies. Gymnotic uptake potential is evaluated for ASO programs; delivery modality compatibility is assessed for siRNA programs.

(4) Delivery strategy selection: For siRNA programs, LNP formulation evaluation, GalNAc conjugation potency validation, and in vitro targeting assays facilitate identification of the optimal delivery platform.

(5) In vivo study design: Long-duration in vitro efficacy validation and repeat-dose simulation studies support prediction of in vivo outcomes, optimization of dosing regimens, and reduction of animal study costs.

(6) Development risk mitigation: Multi-dimensional assessments enable early identification of critical safety risks—including off-target toxicity, immunogenicity (siRNA), and hepatotoxicity—thereby de-risking subsequent development.

5. Deliverable Highlights

ZhuHai GeneRulor delivers more than experimental data—we provide a complete decision-support framework. Each phase report is professionally analyzed and visualized to enable clients to rapidly interpret results and make well-informed decisions.

5.1 Primary Screening (Rapid Identification of High-Potential Candidates)

Concentration-gradient screening combined with a composite scoring system provides intuitive visualization of potency profiles and dose-dependency for each candidate. Reports include candidate composite rankings, preliminary off-target risk evaluation (siRNA-specific), and a curated Top 5 recommendation list with optimization guidance.

Deliverable Highlights: Heatmap visualization | Composite score ranking | QC data integrity verification

5.2   Lead Optimization (Precise Assessment of Drug-like Potential)

Complete dose-response curves and therapeutic window analysis, combined with dual mRNA/protein-level confirmation, enable precise calculation of key parameters including IC50 and CC50. For siRNA candidates, additional dedicated data are provided: passenger strand off-target assessment, immunogenicity testing, and durability validation. Multi-dimensional radar plots facilitate intuitive comparison of the overall profiles of Top candidates.

Deliverable Highlights: Multi-dimensional composite scoring | In vivo translational potential prediction

5.3 Lead Confirmation (Delivery Strategy Matching and In Vivo Prediction)

Modality-specific validation is provided: gymnotic uptake assessment for ASOs predicts direct in vivo delivery potential; LNP/GalNAc delivery efficiency validation for siRNAs evaluates compatibility with different delivery platforms. Long-duration efficacy validation (96–120 h) provides critical reference data for in vivo dosing regimen design. A comprehensive Lead molecule evaluation report is delivered as the final output.

Deliverable Highlights: Delivery strategy compatibility assessment | In vivo efficacy prediction | IND-ready data package

6. Service Menu and Timelines

*Timelines exclude chemical synthesis (3–4 weeks). Expedited service available. Specific programs are tailored to project requirements.

7. Sample Submission Requirements

8. References

[1] U.S. Food and Drug Administration. Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics Guidance for Industry. Draft Guidance. November (2024).

[2] Andersson, P. et al. Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations. Nucleic Acid Ther. (2024).

[3] Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 2010 Jan;38(1):e3.

[4] Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017 Nov;377(18):1723-1732.

[5] Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul;379(1):11-21.

[6] Balwani M, Sardh E, Ventura P, et al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020 Jun;382(24):2289-2301.

[7] Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med. 2021 Apr;384(13):1216-1226.

[8] Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 Apr;382(16):1507-1519.